Mechanism and inhibition of dengue and chikungunya virus fusion protiens
登革热和基孔肯雅病毒融合蛋白的作用机制及抑制作用
基本信息
- 批准号:8230243
- 负责人:
- 金额:$ 44.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAlphavirusAnimalsAntiviral AgentsAntiviral TherapyBindingBiological AssayCase StudyCategoriesChikungunya virusChimeric ProteinsCollaborationsCountryCulicidaeDengue VirusDillDisease OutbreaksDominant-Negative MutationEncephalitisFlavivirusFlavivirus InfectionsFluorescenceGoalsGrantHumanIndiaInfectionLeadMediatingMembrane FusionMolecular ConformationProteinsReactionRecombinant ProteinsRecombinantsResearchSemliki forest virusSiteSpecificityStructureSystemTestingTicksUnited States National Institutes of HealthViralViral Hemorrhagic FeversVirusVirus DiseasesVirus Inhibitorsbasebiodefenseglobal healthhigh throughput screeningin vitro Assayinhibitor/antagonistmembernovelpathogensmall moleculesmall molecule librariestooltrimer corevector
项目摘要
Flaviviruses and alphaviruses are spread by mosquito and tick vectors and cause severe human and
animal illnesses such as encephalitis and hemorrhagic fever. These viruses include potential bioterrorist
agents that are category A-C pathogens, such as the flavivirus dengue virus (DV) and the alphavirus
Chikungunya virus (CV). DV is of particular concern as it has dramatically reemerged to become endemic in
more than 100 countries including the US, and is now a global health problem. Alphaviruses can also be
important emerging pathogens, as exemplified by the recent outbreak of CV infection with several million
cases reported to date in India. Antiviral strategies for the flaviviruses and alphaviruses are urgently needed.
The flavivirus and alphavirus membrane fusion proteins are members of the class II virus membrane
fusion proteins. They are structurally very similar and refold to a homotrimer form to mediate virus fusion and
infection. In collaboration with Dr. Felix Rey, we determined the structure of the homotrimer conformation of
the fusion protein from the alphavirus Semliki Forest virus (SFV). The SFV homotrimer structure is strikingly
similar to that of DV. Using the structures as a guide, we have recently developed recombinant forms of
domain III (DUN) from the SFV and DV fusion proteins. These recombinant Dill proteins act as specific
dominant-negative inhibitors of virus fusion and infection, and are the basis for our proposed screen for small
molecule inhibitors of DV and CV.
In aim 1 we will use our recombinant protein systems to define the mechanism of DV and CV fusion
protein trimerization and the steps in trimer formation. In aim 2, we will develop fluorescence-based in vitro
assays for the binding of DIM to the trimer core of DV and CV. In aim 3 we will adapt this assay to a high
throughput format. We will then use the assay in high throughput screens of small molecule libraries
available through the NIH and the Northeast Biodefense Consortium, and validate hits by tests of virus fusion
and infection. Ultimately, such inhibitors will be lead compounds for antiviral therapy, and important research
tools to understand the class II virus fusion reaction.
黄病毒和甲病毒由蚊子和蜱虫传播,可引起严重的人类感染
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET KIELIAN其他文献
MARGARET KIELIAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET KIELIAN', 18)}}的其他基金
Project 6 - Development of Antivirals against Alphaviruses
项目 6 - 开发抗甲病毒的抗病毒药物
- 批准号:
10513947 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Identification and characterization of host proteins involved in the alphavirus exit pathway
甲病毒退出途径中宿主蛋白的鉴定和表征
- 批准号:
10495264 - 财政年份:2021
- 资助金额:
$ 44.18万 - 项目类别:
Identification and characterization of host proteins involved in the alphavirus exit pathway
甲病毒退出途径中宿主蛋白的鉴定和表征
- 批准号:
10352876 - 财政年份:2021
- 资助金额:
$ 44.18万 - 项目类别:
Mechanism and inhibition of dengue and chikungunya virus fusion protiens
登革热和基孔肯雅病毒融合蛋白的作用机制及抑制作用
- 批准号:
7670803 - 财政年份:2009
- 资助金额:
$ 44.18万 - 项目类别:
Molecular Analysis of Alphavirus Membrane Fusion Protein
甲病毒膜融合蛋白的分子分析
- 批准号:
7919163 - 财政年份:2009
- 资助金额:
$ 44.18万 - 项目类别:
Molecular Mechanisms of Alphavirus Entry and Exit
甲病毒进入和退出的分子机制
- 批准号:
7922849 - 财政年份:2009
- 资助金额:
$ 44.18万 - 项目类别:
Inhibition of the Membrane Fusion Proteins of Flaviviruses and Alphaviruses
黄病毒和甲病毒膜融合蛋白的抑制
- 批准号:
7255226 - 财政年份:2007
- 资助金额:
$ 44.18万 - 项目类别:
Inhibition of the Membrane Fusion Proteins of Flaviviruses and Alphaviruses
黄病毒和甲病毒膜融合蛋白的抑制
- 批准号:
7414889 - 财政年份:2007
- 资助金额:
$ 44.18万 - 项目类别:
MOLECULAR MECHANISMS OF ALPHAVIRUS ENTRY AND EXIT
甲病毒进入和退出的分子机制
- 批准号:
6351246 - 财政年份:1999
- 资助金额:
$ 44.18万 - 项目类别:
Molecular Mechanisms of Alphavirus Entry and Exit
甲病毒进入和退出的分子机制
- 批准号:
7340508 - 财政年份:1999
- 资助金额:
$ 44.18万 - 项目类别:
相似海外基金
Intracellular functions and mechanisms of alphavirus ion channel 6K
甲病毒离子通道6K的细胞内功能和机制
- 批准号:
10727819 - 财政年份:2023
- 资助金额:
$ 44.18万 - 项目类别:
Elucidating the mechanisms of alphavirus subgenomic RNA translation
阐明甲病毒亚基因组 RNA 翻译机制
- 批准号:
10678281 - 财政年份:2023
- 资助金额:
$ 44.18万 - 项目类别:
Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
交叉保护性新世界脑炎甲病毒亚单位疫苗的研制
- 批准号:
10696914 - 财政年份:2023
- 资助金额:
$ 44.18万 - 项目类别:
Defining the Molecular Determinants of Encephalitic Alphavirus Viremia
定义脑炎甲病毒血症的分子决定因素
- 批准号:
10599124 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Defining the Molecular Determinants of Encephalitic Alphavirus Viremia
定义脑炎甲病毒血症的分子决定因素
- 批准号:
10384551 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Center of Excellence for Encephalitic Alphavirus Therapeutics
脑炎甲病毒治疗卓越中心
- 批准号:
10631703 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1
甲病毒感染性和适应机制 - 重新提交 - 1
- 批准号:
10556424 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Structural Mechanisms of Alphavirus Membrane Fusion
甲病毒膜融合的结构机制
- 批准号:
10444088 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Structural Mechanisms of Alphavirus Membrane Fusion
甲病毒膜融合的结构机制
- 批准号:
10612929 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:
Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1
甲病毒感染性和适应机制 - 重新提交 - 1
- 批准号:
10444392 - 财政年份:2022
- 资助金额:
$ 44.18万 - 项目类别:














{{item.name}}会员




